ONO-4685 is under clinical development by Ono Pharmaceutical and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ONO-4685’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ONO-4685 overview

ONO-4685 is under development for the treatment of autoimmune diseases, peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), nodal PTCL with T-follicular helper (TFH) and follicular T-cell lymphoma (FTCL), cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), Sezary syndrome (SS) and plaque psoriasis. It is administered by intravenous route and parenteral route. The drug candidate is a bi-specific monoclonal antibody that targets programmed cell death protein 1 (PD1) and CD3. The drug candidate is a new chemical entity.

Ono Pharmaceutical overview

Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.

For a complete picture of ONO-4685’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.